R
Rossen Koytchev
Publications - 15
Citations - 368
Rossen Koytchev is an academic researcher. The author has contributed to research in topics: Erythropoietin & Epoetin Zeta. The author has an hindex of 11, co-authored 14 publications receiving 342 citations.
Papers
More filters
Journal ArticleDOI
Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment
TL;DR: Etroetin zeta is therapeutically equivalent to epoetin alfa in the maintenance of target Hb levels in patients with renal anaemia and chronic kidney disease maintained on haemodialysis.
Journal ArticleDOI
Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia.
Stefan Krivoshiev,Vasil V Todorov,Jacek Manitius,Stanisław Czekalski,Paul Scigalla,Rossen Koytchev +5 more
TL;DR: Etroetin zeta, administered intravenously, is therapeutically equivalent to epoetin alfa in the correction of low Hb concentration in patients with CKD undergoing haemodialysis.
Journal ArticleDOI
Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Stefan Krivoshiev,Volker Wizemann,Stanisław Czekalski,Adalbert Schiller,Steva Plješa,Michael Wolf-Pflugmann,Marianne Siebert-Weigel,Rossen Koytchev,Angelika Bronn +8 more
TL;DR: Epoetin zeta, administered subcutaneously, is equivalent to epoetin alfa in respect of its clinical efficacy and the safety profile of both products is similar: no unexpected AEs were observed, no patients developed anti-erythropoietin antibodies, and both epOetin preparations were well tolerated.
Journal ArticleDOI
Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia
Conrad A. Baldamus,Stefan Krivoshiev,Michael Wolf-Pflugmann,Marianne Siebert-Weigel,Rossen Koytchev,Angelika Bronn +5 more
TL;DR: The results suggest that intravenous administration of epoetin zeta is effective regarding its ability to maintain stabilized hemoglobin levels within the target range of 10.5–12.5 g/dL, and there were no reports of patients with increasing erythropoietin resistance.
Journal ArticleDOI
Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
TL;DR: Epoetin zeta is a recently introduced recombinant erythropoietin, designed to be biologically similar to epoetin alfa, that can be interchanged without any clinically significant alteration in efficacy, safety, or epoETin dose, in patients with CKD on dialysis receiving stable epOetin maintenance therapy.